[go: up one dir, main page]

WO2009033810A3 - Utilisation d'un peptide en tant qu'agent thérapeutique - Google Patents

Utilisation d'un peptide en tant qu'agent thérapeutique Download PDF

Info

Publication number
WO2009033810A3
WO2009033810A3 PCT/EP2008/008153 EP2008008153W WO2009033810A3 WO 2009033810 A3 WO2009033810 A3 WO 2009033810A3 EP 2008008153 W EP2008008153 W EP 2008008153W WO 2009033810 A3 WO2009033810 A3 WO 2009033810A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
disease
phckrm
aplha
casein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/008153
Other languages
English (en)
Other versions
WO2009033810A2 (fr
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mondobiotech Laboratories AG
Original Assignee
Mondobiotech Laboratories AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Laboratories AG filed Critical Mondobiotech Laboratories AG
Publication of WO2009033810A2 publication Critical patent/WO2009033810A2/fr
Publication of WO2009033810A3 publication Critical patent/WO2009033810A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de la combinaison des composés peptidiques Pro-His-Cys-Lys-Arg-Met-OH et Arg-Tyr-Leu-Gly-Tyr-Leu-Glu-OH en tant que composés polythérapeutiques destinés à la prophylaxie et/ou au traitement du cancer, d'une maladie cardiaque et vasculaire, d'une maladie infectieuse, d'une maladie fibreuse, d'une maladie inflammatoire, d'une maladie neurodégénérative ou d'une maladie auto-immune.
PCT/EP2008/008153 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique Ceased WO2009033810A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017747.2 2007-09-11
EP07017749.8 2007-09-11
EP07017747 2007-09-11
EP07017749 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009033810A2 WO2009033810A2 (fr) 2009-03-19
WO2009033810A3 true WO2009033810A3 (fr) 2009-10-22

Family

ID=40452594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008153 Ceased WO2009033810A2 (fr) 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique

Country Status (1)

Country Link
WO (1) WO2009033810A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2673374A1 (fr) * 1991-03-01 1992-09-04 Oreal Composition cosmetique contenant comme ingredient actif un peptide a activite opiouide.
JPH09176187A (ja) * 1995-12-27 1997-07-08 Kagaku Gijutsucho Hoshasen Igaku Sogo Kenkyusho 活性酸素消去能を有するヒスチジン含有ペプチド
JP2001213897A (ja) * 2000-02-03 2001-08-07 Kagome Co Ltd オピオイドペプチド及びその製造法
EP1188767A1 (fr) * 2000-08-28 2002-03-20 Kraft Foods Holdings, Inc. Peptides dérivées de la caséine ayant des propriétés anti-oxidatives et méthodes pour identifier et isoler des peptides ayant lesdites propriétés
WO2008071755A2 (fr) * 2006-12-13 2008-06-19 Institut National Polytechnique De Lorraine Peptides derives de la caseine ayant une activité anxiolytique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2673374A1 (fr) * 1991-03-01 1992-09-04 Oreal Composition cosmetique contenant comme ingredient actif un peptide a activite opiouide.
JPH09176187A (ja) * 1995-12-27 1997-07-08 Kagaku Gijutsucho Hoshasen Igaku Sogo Kenkyusho 活性酸素消去能を有するヒスチジン含有ペプチド
JP2001213897A (ja) * 2000-02-03 2001-08-07 Kagome Co Ltd オピオイドペプチド及びその製造法
EP1188767A1 (fr) * 2000-08-28 2002-03-20 Kraft Foods Holdings, Inc. Peptides dérivées de la caséine ayant des propriétés anti-oxidatives et méthodes pour identifier et isoler des peptides ayant lesdites propriétés
WO2008071755A2 (fr) * 2006-12-13 2008-06-19 Institut National Polytechnique De Lorraine Peptides derives de la caseine ayant une activité anxiolytique

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANASPEC, INC.: "Antioxidant peptide A", 17 July 2009 (2009-07-17), pages 1 - 1, XP002537744, Retrieved from the Internet <URL:http://www.anaspec.com/products/product.asp?id=30525> [retrieved on 20090717] *
AZQFAN: "Bionova skincare with nano technology on at 1 a.m", 27 April 2008 (2008-04-27), pages 1 - 8, XP002537745, Retrieved from the Internet <URL:http://community.qvc.com/topic/Beauty-Banter/Bionova-Skincare-Nano/5700022656> [retrieved on 20090717] *
DATABASE WPI Week 199737, Derwent World Patents Index; AN 1997-399524, XP002537747 *
DATABASE WPI Week 200173, Derwent World Patents Index; AN 2001-629609, XP002537309 *
GOBBETTI MARCO ET AL: "Angiotensin I-converting-enzyme-inhibitory and antimicrobial bioactive peptides", INTERNATIONAL JOURNAL OF DAIRY TECHNOLOGY, & 2003 SYMPOSIUM TO MARK THE 40TH YEAR SINCE THE PUBLICATION PAPER; CORK, IRELAND; OCTOBER 22, 2003, vol. 57, no. 2-3, 1 May 2004 (2004-05-01), pages 173 - 188, XP002537005 *
HATZOGLOU ANASTASSIA ET AL: "Antiproliferative and receptor binding properties of alpha- and beta-casomorphins in the T47D human breast cancer cell line", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 310, no. 2-3, 1996, pages 217 - 223, XP002537306, ISSN: 0014-2999 *
JAKUB FICHNA ET AL: "Opioid peptides in cancer", CANCER AND METASTASIS REVIEWS, KLUWER ACADEMIC PUBLISHERS, DO, vol. 23, no. 3-4, 1 August 2004 (2004-08-01), pages 351 - 366, XP019205160, ISSN: 1573-7233 *
KAMPA MARILENNA ET AL: "Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 335, no. 2-3, 1997, pages 255 - 265, XP002537307, ISSN: 0014-2999 *
LOUKAS S ET AL: "OPIOID ACTIVITIES AND STRUCTURES OF ALPHA CASEIN DERIVED EXORPHINS", BIOCHEMISTRY, vol. 22, no. 19, 1983, pages 4567 - 4573, XP002537308, ISSN: 0006-2960 *
NILSSON ANNA-MALIN ET AL: "A conjugated diene identified as a prohapten: Contact allergenic activity and chemical reactivity of proposed epoxide metabolites", CHEMICAL RESEARCH IN TOXICOLOGY, vol. 18, no. 2, February 2005 (2005-02-01), pages 308 - 316, XP002537746, ISSN: 0893-228X *

Also Published As

Publication number Publication date
WO2009033810A2 (fr) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009033821A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033797A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009043518A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
IL184424A0 (en) Cxcr4 antagonists for the treatment of hiv infection
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2010057101A3 (fr) Composés utiles en tant qu’inhibiteurs de vih
WO2009026179A3 (fr) Composés de proanthocyanidine anti-infectieux et leurs procédés d&#39;utilisation
HK1198869A1 (en) Combination treatments for hepatitis c
WO2012046030A3 (fr) Inhibiteurs de phosphodiestérase
GEP201706656B (en) 2-thiopyrimidinones
WO2009033819A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2016146812A3 (fr) Traitement de patients atteints de diabète de type 2
WO2009033813A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009043525A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2012138911A3 (fr) Conjugués de médicaments anti-vih et d&#39;analogues de somatostatine
WO2009046875A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033814A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033818A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033820A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
HK1199201A1 (en) Antimicrobial peptides for treatment of infectious diseases
WO2006089664A3 (fr) Imidazoles substitues par heterocyclylamide
WO2009046872A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033816A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831189

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08831189

Country of ref document: EP

Kind code of ref document: A2